We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cell Viability Tests Compared with Microchip Method

By LabMedica International staff writers
Posted on 12 Apr 2011
A technique for the automatic cell viability measurement with a microscopic cell counter and microchip has been evaluated. More...


An appraisal has been made of different methods of cell viability testing, an essential tool for performing cell-based studies and clinical laboratory tests.

Scientists at Korea University Guro Hospital (Seoul, Korea) compared three different methods to test the viability of blood cells. Blood was drawn from 11 healthy volunteers and mononuclear cells were separated immediately from the heparinized whole blood, and the viable cells were diluted subsequently down from 100% to, 75%, 50%, 25%, and 1%. The cell viability tests were performed simultaneously with the following three methods: the conventional manual trypan blue exclusion method; the flow cytometry measurement with propidium iodide stain; and the newly developed automated fluorescence microscopic cell counter with microchip.

The linearity, precision, and correlations from three methods were analyzed and compared. The correlations data from the microscopic cell counter were in good agreement with both the conventional trypan blue method and the flow cytometry. The precision and linearity from the microscopic cell counter method with microchip were superior in comparison with the conventional method. The new microscopic cell counter with microchip, known as Adam (NanoenTek, Inc.; Seoul, Korea), was further developed and improved to produce the results within five minutes, including all procedural steps.

In the manual trypan blue stain, only 200 cells were counted to measure their viability, but in Adam, larger number of cells, approximately between 1,000 and 3,000 cells, were counted. Greater number of counted cells and the repetitions of the experiments by the microscopic cell counter and microchip for the analyses provided the better statistical significance. The real-time cellular images and archived data could also be used for analyzing other parameters. The study was published online on March 15, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:
Korea University Guro Hospital
NanoenTek, Inc.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.